<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04308564</url>
  </required_header>
  <id_info>
    <org_study_id>2019-A02058-49</org_study_id>
    <nct_id>NCT04308564</nct_id>
  </id_info>
  <brief_title>Laboratory and Clinical Data in Antiphospholipid Patients</brief_title>
  <acronym>APSregistry</acronym>
  <official_title>Constitution d'Une Collection d'Echantillons Biologiques Associee a Une Base de Donnees de Patients Possedant Des Anticorps Antiphospholipides</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Central Hospital, Nancy, France</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Central Hospital, Nancy, France</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To constitute a registry of antiphospholipid antibodies positive-patients
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      An international web-based application, the REDCap (Research Electronic Data Capture),
      captures data on patient demographics, aPL-related clinical and laboratory characteristics,
      and medications. The inclusion criteria are: a) age between 18 and 60 years; and b)
      persistent (at least 12 weeks apart) aPL-positivity within 12 months prior to screening;
      positivity is defined as anticardiolipin antibodies (aCL) IgG/M/A (&gt; 40 GPL/MPL/APL,
      medium-to-high titer, and/or greater than the 99th percentile), anti-β2-glycoprotein-I
      (aβ2GPI) IgG/M/A (&gt; 40 units, medium-to-high titer), positive lupus anticoagulant (LA) test
      based on International Society on Thrombosis and Hemostasis and other current guidelines.
      Patients are followed every 12 ± 3 months with clinical data and blood collection. Blood
      drawn is done at inclusion and every year.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">October 1, 2020</start_date>
  <completion_date type="Anticipated">April 1, 2031</completion_date>
  <primary_completion_date type="Anticipated">April 1, 2030</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>10 Years</target_duration>
  <primary_outcome>
    <measure>Thrombosis</measure>
    <time_frame>Up to 10 years</time_frame>
    <description>Rate of thrombosis</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Bleeding</measure>
    <time_frame>Up to 10 years</time_frame>
    <description>Rate of bleeding</description>
  </secondary_outcome>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Antiphospholipid Syndrome</condition>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Blood test</intervention_name>
    <description>Blood test for the identification of biomarkers</description>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      DNA, plasma and serum
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Antiphospholipid antibodies positive-patients
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  age between 18 and 60 years;

          -  persistent (at least 12 weeks apart) aPL-positivity within 12 months prior to
             screening

        Exclusion Criteria:

          -  no inform consent

          -  impossible follow up

          -  pregnancy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>CHRU de Lille</name>
      <address>
        <city>Lille</city>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Eric Hachulla</last_name>
    </contact>
    <investigator>
      <last_name>Eric Hachulla, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Marc Lambert, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Cécile Yelnik, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHRU de Nancy</name>
      <address>
        <city>Nancy</city>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Denis Wahl, MD, PhD</last_name>
      <phone>+33383153614</phone>
      <email>d.wahl@chru-nancy.fr</email>
    </contact>
    <investigator>
      <last_name>Denis Wahl, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Stéphane Zuily, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Virginie Dufrost, MD, MSc</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>March 9, 2020</study_first_submitted>
  <study_first_submitted_qc>March 11, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">March 16, 2020</study_first_posted>
  <last_update_submitted>July 13, 2020</last_update_submitted>
  <last_update_submitted_qc>July 13, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 14, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Central Hospital, Nancy, France</investigator_affiliation>
    <investigator_full_name>Pr Denis WAHL</investigator_full_name>
    <investigator_title>Head of Vascular Medicine Division, Principal Investigator, Professor of Vascular Medicine</investigator_title>
  </responsible_party>
  <keyword>antiphospholipid antibodies</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antiphospholipid Syndrome</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

